Swissray delisted from NASDAQSwissray International's securities have been delisted from the NASDAQ stock exchange. The delisting took effect at the close of business Oct. 26. According to the NASDAQ delisting panel, the exchange made the move
Swissray International's securities have been delisted from the NASDAQ stock exchange. The delisting took effect at the close of business Oct. 26. According to the NASDAQ delisting panel, the exchange made the move because Swissray shares had fallen below $1 for several months, and the company had failed to file its 10-K report for fiscal year ending June 30 before an Oct. 15 extension.
The decision came only weeks after New York City-based Swissray had taken measures to bolster its stock value with a reverse stock split (PNN 9/98). According to the company, its shares had been trading above the $1 minimum for 17 consecutive trading days.
NASDAQ's Listing and Hearing Review Council may review any panel decision within 45 calendar days after a written decision is issued. A company may also request that the review council revisit its decision within 15 days of the date of the decision. However, a review, requested either by a company or by the NASDAQ review council, does not act as a stay to the decision. Swissray intends to request review of the Oct. 26 delisting decision and continues to work toward filing its 10-K, according to the company.
In other Swissray news, the company has entered into a reseller relationship with FileLink for that company's FileLink Medical Archive Software, which will serve as a low-end optional archive solution for the AddOnMulti-System. The Windows NT-based MAS supports DICOM and is also capable of storing and retrieving nonDICOM information from the same server, according to Minneapolis, MN-based File Link. Swissray will market the software in the U.S. and Europe and has already installed it at two sites in conjunction with the AddOnMulti-System. Swissray's PACS distribution deal with EMED is unaffected by the arrangement with FileLink, said Michael Baker, CEO of Swissray Information Solutions.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.